Impact of the COVID-19 pandemic on the prescription of disease-modifying therapy for multiple sclerosis in England: a nationwide study

J Neurol Neurosurg Psychiatry. 2022 Mar 10;93(11):1229-1230. doi: 10.1136/jnnp-2021-328340. Online ahead of print.

Authors

Thomas Williams^{1

2}, Rhea Mishra³, Brina Bharkhada², Aoife Shields², Rachel Dorsey⁴, Jeremy Chataway^{5

2}, Wallace J Brownlee^{5

2}

Affiliations

¹ Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London, London, UK [email protected].
² National Hospital for Neurology and Neurosurgery, London, UK.
³ NHS England, Redditch, UK.
⁴ Department of Neurology, Imperial Healthcare NHS Trust, London, UK.
⁵ Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London, London, UK.

No abstract available

Keywords: COVID-19; multiple sclerosis.

Publication types

Letter